These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 24353323)
81. Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Wang Y; Sedimbi S; Löfbom L; Singh AK; Porcelli SA; Cardell SL Mucosal Immunol; 2018 Jan; 11(1):131-143. PubMed ID: 28401935 [TBL] [Abstract][Full Text] [Related]
82. High Dimensionality Reduction and Immune Phenotyping of Natural Killer and Invariant Natural Killer Cells in Latent Tuberculosis-Diabetes Comorbidity. Kathamuthu GR; Kumar NP; Moideen K; Menon PA; Babu S J Immunol Res; 2022; 2022():2422790. PubMed ID: 35242883 [TBL] [Abstract][Full Text] [Related]
83. Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia. Braun NA; Mendez-Fernandez YV; Covarrubias R; Porcelli SA; Savage PB; Yagita H; Van Kaer L; Major AS Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1758-65. PubMed ID: 20539017 [TBL] [Abstract][Full Text] [Related]
84. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy. Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL Front Immunol; 2019; 10():352. PubMed ID: 30881361 [TBL] [Abstract][Full Text] [Related]
85. Innate-like and conventional T cell populations from hemodialyzed and kidney transplanted patients are equally compromised. Baron M; Belo R; Cathelin D; Moreira-Teixeira L; Cartery C; Rondeau E; Mesnard L; Leite-de-Moraes M PLoS One; 2014; 9(8):e105422. PubMed ID: 25144742 [TBL] [Abstract][Full Text] [Related]
86. Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Cohen NR; Brennan PJ; Shay T; Watts GF; Brigl M; Kang J; Brenner MB; Nat Immunol; 2013 Jan; 14(1):90-9. PubMed ID: 23202270 [TBL] [Abstract][Full Text] [Related]
87. Pathogen-expanded CD11b+ invariant NKT cells feedback inhibit T cell proliferation via membrane-bound TGF-β1. Han Y; Jiang Z; Chen Z; Gu Y; Liu Y; Zhang X; Cao X J Autoimmun; 2015 Apr; 58():21-35. PubMed ID: 25592391 [TBL] [Abstract][Full Text] [Related]
88. Preferential and persistent impact of acute HIV-1 infection on CD4 Paquin-Proulx D; Lal KG; Phuang-Ngern Y; Creegan M; Tokarev A; Suhkumvittaya S; Alrubayyi A; Kroon E; Pinyakorn S; Slike BM; Bolton DL; Krebs SJ; Eller LA; Sajjaweerawan C; Pagliuzza A; Chomont N; Rerknimitr R; Chomchey N; Phanuphak N; de Souza MS; Michael NL; Robb ML; Ananworanich J; Sandberg JK; Eller MA; Schuetz A; ; ; ; Proc Natl Acad Sci U S A; 2021 Nov; 118(46):. PubMed ID: 34753817 [TBL] [Abstract][Full Text] [Related]
89. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide. Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753 [TBL] [Abstract][Full Text] [Related]
90. High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity. Erkers T; Xie BJ; Kenyon LJ; Smith B; Rieck M; Jensen KP; Ji X; Basina M; Strober S; Negrin RS; Maecker HT; Meyer EH Blood; 2020 Mar; 135(11):814-825. PubMed ID: 31935280 [TBL] [Abstract][Full Text] [Related]
91. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; Hooijberg E; Kramer D; Reurs AW; van den Eertwegh AJ; von Blomberg BM; Scheper RJ; Bontkes HJ J Immunol; 2008 Aug; 181(4):2446-54. PubMed ID: 18684935 [TBL] [Abstract][Full Text] [Related]
92. Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection. Paquin-Proulx D; Ching C; Vujkovic-Cvijin I; Fadrosh D; Loh L; Huang Y; Somsouk M; Lynch SV; Hunt PW; Nixon DF; SenGupta D Mucosal Immunol; 2017 Jan; 10(1):69-78. PubMed ID: 27049061 [TBL] [Abstract][Full Text] [Related]
93. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody. Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408 [TBL] [Abstract][Full Text] [Related]